Oncodesign Precision Medicine SA () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Oncodesign Precision Medicine SA

Why is Oncodesign Precision Medicine SA ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Oncodesign Precision Medicine SA for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Oncodesign Precision Medicine SA

20.0%

-0.39

146.47%

France CAC 40

0.34%

0.02

17.51%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

0.00%

EBIT Growth (5y)

0.00%

EBIT to Interest (avg)

-9.49

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.61

Sales to Capital Employed (avg)

0.06

Tax Ratio

13.25%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.66

EV to EBIT

2.79

EV to EBITDA

2.65

EV to Capital Employed

1.40

EV to Sales

14.24

PEG Ratio

Dividend Yield

ROCE (Latest)

50.05%

ROE (Latest)

102.33%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

ROCE(HY)

Highest at 209.56%

RAW MATERIAL COST(Y)

Fallen by -1,069.8% (YoY

OPERATING PROFIT(Q)

Highest at EUR 9.66 MM

PRE-TAX PROFIT(Q)

Highest at EUR 9.53 MM

NET PROFIT(Q)

Highest at EUR 9.85 MM

EPS(Q)

Highest at EUR 0.54

-1What is not working for the Company

INVENTORY TURNOVER RATIO(HY)

Lowest at -0.7 times

Here's what is working for Oncodesign Precision Medicine SA

Pre-Tax Profit

At EUR 9.53 MM has Grown at 322.39%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (EUR MM)

Net Profit

At EUR 9.85 MM has Grown at 370.8%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (EUR MM)

Operating Profit

Highest at EUR 9.66 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (EUR MM)

Pre-Tax Profit

Highest at EUR 9.53 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (EUR MM)

Net Profit

Highest at EUR 9.85 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (EUR MM)

EPS

Highest at EUR 0.54

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (EUR)

Raw Material Cost

Fallen by -1,069.8% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Oncodesign Precision Medicine SA

Inventory Turnover Ratio

Lowest at -0.7 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio